UBS Group’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

UBS Group’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-59	Closed	-$4	–	11426
2022 Q4	$4	Sell	59 -25,136	-100%	-$960	﹤0.01%	10633
2022 Q3	$2K	Sell	25,195 -1,449	-5%	-$84	﹤0.01%	9875
2022 Q2	$2K	Buy	26,644 +24,160	+973%	+$4.99K	﹤0.01%	9738
2022 Q1	$1K	Sell	2,484 -190	-7%	-$61	﹤0.01%	10064
2021 Q4	$2K	Buy	+2,674	New	+$1.85K	﹤0.01%	9901

UBS Group's BIOTW Position: Q1 2023 in Review

UBS Group sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 59 shares — an estimated $4 sold.

UBS Group first reported a position in BIOTW in Q4 2021 and held it in 5 quarters. The position peaked at $2K in Q3 2022. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

UBS Group reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
UBS Group sold 59 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $4.
UBS Group first reported a position in Biotech Acquisition Company Warrant in Q4 2021 and held it in 5 quarters.
UBS Group's Biotech Acquisition Company Warrant position peaked at $2K in Q3 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.